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ORIGINAL ARTICLENational epidemiology of carbapenem-resistant and extensively
drug-resistant Gram-negative bacteria isolated from blood samples in
China in 2013A. Xu1, B. Zheng2, Y.-C. Xu3, Z.-G. Huang1, N.-S. Zhong1 and C. Zhuo1
1) State Key Laboratory of Respiratory Diseases, The First Afﬁliated Hospital of Guangzhou Medical College, Guangzhou, 2) The First Teaching Hospital of Beijing
University and 3) Peking Union Medical College Hospital, Beijing, ChinaAbstractAlthough antimicrobial resistance poses a great challenge to clinicians in China, there are limited antimicrobial resistance data on Gram-
negative bacteria nationwide. We investigated the phenotypic characteristics of carbapenem-resistant Escherichia coli (CREC) and Klebsiella
pneumoniae (CRKP) as well as extensively drug-resistant strains of Pseudomonas aeruginosa (XDRPA) and Acinetobacter baumannii
(XDRAB) isolated from blood cultures in China. Data were collected on 24 113 isolates from the China surveillance of antimicrobial
resistance program in 2013, which comprised 208 hospitals located in all seven administrative regions of China. Minimum inhibitory
concentrations (MICs) for common antimicrobials were determined by commercial automated systems available at local hospitals, and
associations with geographic and clinical distributions was further studied. The overall prevalence of CREC, CRKP, XDRAB and XDRPA
strains was 1.0, 5.5, 13.7 and 4.2%, respectively. Except for CREC, which did not differ greatly by region, the prevalence of the remaining
three strains varied signiﬁcantly across regions. The highest prevalence of CRKP (10.6%) and XDRAB (13.1%) were found in the pediatric
group, and higher prevalence of all four target strains was found in the intensive care unit. For imipenem, 55.8% of CREC and 22.9% of
CRKP strains had MICs of 4 μg/mL, while 97.4% XDRAB and 84% XDRPA isolates had MICs of 16 μg/mL. All CREC, CRKP and
81.2% of XDRAB strains were susceptible to tigecycline, with MIC90 values of 0.5, 2 and 4 μg/mL, respectively. In conclusion, a high
prevalence of CRKP and XDRAB has emerged in China, especially in children and in the intensive care unit.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: chaosheep@sina.comIntroductionAntimicrobial resistance is a major problem in China, with over
50% of Gram-negative bacilli exhibiting resistance to clinically
important antimicrobial agents in many tertiary-care hospitals
before 2010, including extended-spectrum β-lactamase-Clinical Microbiology and Infection © 2015 The Authors. Published by El
This is an open access artiproducing Escherichia coli, quinolone-resistant E. coli, and
carbapenem-resistant Acinetobacter baumannii (CRAB) [1].
Furthermore, China had the world’s most rapid average resis-
tance growth rate, 22%, for the ten most commonly isolated
bacteria from 1994 to 2000 [2]. The dominant clone of
K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae is
ST11 and of carbapenem-resistant (CR) A. baumannii is CC92 in
multiple provinces of China [3,4]. Consequently, in April 2012,
China’s Health Ministry enacted a policy on the management
method for clinical use of antimicrobials to establish a hierar-
chical management system for clinical use of antibiotics [5]. The
beneﬁts of this policy included a signiﬁcant improvement in the
rational use of antibiotics and a subsequent stabilization [6].Clin Microbiol Infect 2016; 22: S1–S8
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S2 Clinical Microbiology and Infection, Volume 22 Number S1, March 2016 CMIInfections caused by some superbugs such as CR and
extensively drug-resistant (XDR) Gram-negative pathogens
pose a great challenge to clinicians in regard to the choice of
appropriate antimicrobial therapy, especially in resource-
constrained settings without access to last-resort antibiotics
such as colistin or tigecycline. Combination regimens involving
carbapenems or aminoglycosides, the available antibiotics in
many regions of China, have been proposed for the treatment
of CR Enterobacteriaceae (CRE) infections because several CREs
had minimum inhibitory concentrations (MICs) for carbape-
nems within the previously susceptible range of 4 mg/L and
also are susceptible to aminoglycosides [7,8].
There are still limited national data on the epidemiologic
characteristics of CR and XDR Gram-negative bacilli in China,
which is essential for monitoring antimicrobial resistance rates
as well as formulating relevant policies for control and man-
agement of these infections. For this purpose, the phenotypic
characteristics of CR E. coli (CREC) and Klebsiella pneumoniae
(CRKP), and XDR strains of Pseudomonas aeruginosa (XDRPA)
and A. baumannii (XDRAB) isolates obtained from blood were
studied. Antimicrobial susceptibility and MIC distribution for
available drugs were determined and analysed in relation to
geographic locale and clinical information.Materials and MethodsTABLE 1. Distribution of Gram-negative bacteria isolated
from blood in China in 2013
Organism Total, n (%) CR, n (%) XDR, n (%)
Escherichia coli 14250 (43.1) 138 (1.0) 133 (0.9)
Klebsiella pneumoniae 6061 (18.5) 333 (5.5) 325 (5.4)
Pseudomonas aeruginosa 1940 (5.9) 317 (16.3) 82 (4.2)
Acinetobacter baumannii 1862 (5.6) 1001 (53.5) 256 (13.7)
Enterobacter cloacae 1296 (3.9) 81 (6.3) 70 (5.4)
Serratia marcescens 847 (2.6) 36 (4.3) 35 (4.1)
Stenotrophomonas maltophilia 842 (2.5) ND ND
Klebsiella oxytoca 486 (1.5) 41 (8.4) 34 (7)
Burkholderia cepacia 429 (1.3) ND ND
Enterobacter aerogenes 331 (1.0) 24 (7.3) 21 (6.3)
Other 4625 (14.0) ND ND
Total 33028 (100.0) ND ND
CR, carbapenem resistant; ND, no done; XDR, extensively drug resistant.Source of bacterial isolates
This study was based on isolates obtained from the China
surveillance antimicrobial resistance program of 2013, which is
a national laboratory-based multicenter study on antimicrobial
resistance of several bacteria. A total of 208 hospitals were
enrolled onto this surveillance study on the basis of the high
quality of the laboratory testing and available surveillance in-
formation. The 208 hospitals comprised 193 tertiary-care and
15 secondary-care hospitals, which were located in all seven
administrative regions of mainland China; these included 11
hospitals in the Northeast, 34 in the North, 48 in the East, 25 in
the South, 33 in Central, 15 in the Northwest and 42 in the
Southwest region of the country. All the surveillance informa-
tion was reconﬁrmed (by checking for completeness, with any
suspicious data rechecked and unconﬁrmed data removed),
including MIC detection by microbroth diffusion assay and
commercial automated systems, by Peking Union Medical
College Hospital, the national quality control center of anti-
microbial resistance. All the isolates were subcultured on blood
agar and MacConkey agar plates at each laboratory for a purity
check and to conﬁrm species identiﬁcation. The Vitek II GN
card was used (bioMérieux, Marcy l’Etoile, France). Basic clin-
ical information of the patients from whom the isolatesClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceoriginated was retrieved retrospectively and included age,
gender and clinical ward to which the patient was admitted.
Antimicrobial susceptibility
MICs of different antimicrobial agents were determined by
Vitek 2 (bioMérieux, Marcy l’Etoile, France) using software
version 5.04 and the AST-GN13, AST-GN09 and AST-GN16
cards, according to the manufacturer’s instructions. The Vitek
2 extended-spectrum β-lactamase test is included on the AST-
GN13 card for E. coli, K. pneumoniae and Klebsiella oxytoca. The
Advanced Expert System rules were not used for this study.
Results were interpreted following the 2013 Clinical and Lab-
oratory Standards Institute criteria [9]. The MIC interpretive
breakpoints of tigecycline for Enterobacteriaceae as recom-
mended by the US Food and Drug Administration (susceptible,
2 μg/mL; intermediate, 4 μg/mL; resistant, 8 μg/mL) was
applied to A. baumannii [10].
CR and XDR Gram-negative deﬁnition
CR was deﬁned as strains with ertapenem MICs 1 μg/mL,
imipenem MICs 2 μg/mL and/or meropenem MICs 2 μg/mL.
XDR was deﬁned as nonsusceptibility to at least one agent in all
but two or fewer antimicrobial categories (i.e. bacterial isolates
remain susceptible to only one or two categories) according to
European expert consensus [11].ResultsGeneral distribution of isolates
A total of 33 028 isolates of Gram-negative bacteria from blood,
95.4% (23 029/33 028) from hospitalized patients, were studied,
including screening for CR and XDR isolates. Overall, E. coli, K.
pneumoniae, Pseudomonas aeruginosa and A. baumannii accoun-
ted for 73.1% (24 113/33 028) of the total pathogens isolated
from blood (Table 1). Detailed distributions of CREC, CRKP,
XDRPA, XDRAB and other strains are listed in Table 1.European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S1–S8
nses/by-nc-nd/4.0/)
TABLE 2. Geographic distribution of CR and XDR isolates in 2013
Geographic area
Escherichia coli Klebsiella pneumoniae Acinetobacter baumannii Pseudomonas aeruginosa
CR (%) CR (%) CR (%) XDR (%) CR (%) XDR (%)
Nationwide 1.0 5.5 57.9 13.7 16.3 4.2
Northeast 0.2 1.0 72.5 8.3 16.7 3.1
North 1.0 3.9 60.9 11.2 24.4 3.4
East 1.2 9.2 49.7 12.1 15.6 8.0
South 0.4 3.2 48.1 5.8 9.0 3.3
Central 1.2 7.3 51.8 12.5 15.1 4.0
Northwest 1.2 3.6 56.4 20.6a 20.8a 3.1
Southwest 1.0 5.4 65.6 20.4 16.8 1.4
CR, carbapenem resistant; XDR, extensively drug resistant.
aAvailable data could only be obtained from two or three hospitals in this region.
<2%
No data
4–6%
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>8%
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FIG. 1. Distribution of carbapenem-
resistant Klebsiella pneumoniae strains in
2013 by geographic area.
FIG. 2. Prevalence of carbapenem-resistant and extensively dru-
gresistant strains in different age groups. adu, adult; CRECO, carbape-
nem-resistant Escherichia coli; CRKPN, carbapenem-resistant Klebsiella
pneumoniae; ger, geriatric; new, newborn; ped, pediatric; XDRAB,
extensively drug-resistant Acinetobacter baumannii; XDRPAE, exten-
sively drug-resistant Pseudomonas aeruginosa.
CMI Xu et al. Epidemiology of resistant bacteria in China S3Geographic distribution and clinical information of
target strains (CREC, CRKP, XDRPA and XDRAB)
Overall, E. coli had the lowest rate of CR (1.0%), followed by
K. pneumoniae (5.5%), whilst Pseudomonas aeruginosa (16.3%)
had high levels of resistance and A. baumannii very high CR rates
(53.5%) (Table 1). Extensive drug resistance was highest
amongst A. baumannii isolates (13.7%) compared to 4.2% among
P. aeruginosa isolates. CREC, CRKP, XDRAB and XDRPA iso-
lates were found in all seven regions of China (Table 2). Except
for CREC, which did not differ greatly by region, the prevalence
of the remaining three strains varied signiﬁcantly across the
regions, as shown in Table 2. CRKP prevalence ranged from
1.0% in Northeast to 9.2% in East, as illustrated in Fig. 1, and
XDRAB ranged from 5.8% in the South to 20.6% in the
Northwest.
The population distribution revealed higher prevalence of
CRKP in newborn and pediatric groups compared to adults,Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S1–S8
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
TABLE 3. Demographic distribution of isolates in neonatal and
pediatric groups by geographic area in China
Geographic
area
CRKP XDRAB
No.
of KP Neonatal
No.
of KP Pediatric
No.
of AB Pediatric
Northeast 1 0 (0) 26 0 (0.0) 4 0 (0.0)
North 211 14 (6.6) 80 13 (16.3) 21 4 (19.0)
East 29 2 (6.9) 84 8 (9.5) 25 8 (32.0)
South 65 16 (24.6) 83 5 (6.0) 23 1 (4.3)
Central 60 11 (18.3) 79 6 (7.6) 27 0 (0.0)
Northwest 24 0 (0) 23 3 (13.0) 12 0 (0.0)
Southwest 76 7 (9.2) 88 14 (15.9) 25 4 (16.0)
Nationwide 466 50 (10.7) 463 49 (10.6) 137 18 (13.1)
AB, Acinetobacter baumannii; CRKP, carbapenem-resistant Klebsiella pneumoniae; KP,
Klebsiella pneumoniae; XDRAB, extensively drug-resistant Acinetobacter baumannii.
S4 Clinical Microbiology and Infection, Volume 22 Number S1, March 2016 CMIwith respective rates of 10.6 and 10.3%, and a similar situation
was found in XDRAB, with the highest rates of 13.1% in the
pediatric group (Fig. 2). To gain a better understanding of the
reasons behind the high prevalence of CRKP and XDRAB in the
pediatric group, the geographic distribution of these two strains
was analysed. As shown in Table 3, in neonatal populations, the
highest prevalence of CRKP was found in the South region
(24.6%), followed by Central region (18.3%). In the pediatric
group, it shifted to the North (16.3%) and Southwest (15.9%)
regions. Meanwhile, higher prevalence of XDRAB was found in
North (19.0%), Southwest (16.0%) and East regions (32.0%).
In terms of clinical ward distribution, the target strains were
identiﬁed in both intensive care unit (ICU) and non-ICU set-
tings (Fig. 3). Generally the four target strains were detected
more in ICU than non-ICU populations, with the phenomenon
more marked in CRKP (12% vs. 4.2%) and in XDRAB (18.8% vs.
10.1%).FIG. 3. Incidence of carbapenem-resistant and extensively drug-resis-
tant strains in different clinical settings. CRECO, carbapenem-resistant
Escherichia coli; CRKPN, carbapenem-resistant Klebsiella pneumoniae;
ICU, intensive care unit; XDRAB, extensively drug-resistant Acineto-
bacter baumannii; XDRPAE, extensively drug-resistant Pseudomonas
aeruginosa.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceIn vitro susceptibility and MIC distribution
MIC ranges, andMIC50 andMIC90 for themain currently available
clinical antimicrobials against target strains are shown in
Supplementary Table S1. Most CREC and CRKP isolates were
not susceptible to β-lactamase inhibitor combinations, carba-
penems and ﬂuoroquinolones, and 50% were susceptible to
aminoglycosides. The XDRAB isolates had higher susceptibility
rates to polymyxin B (96.6%) and tigecycline (84.8%), whilst the
XDRPA isolates had the highest susceptibility rate to polymyxin
B (77.8%). MIC distribution analysis displayed that 55.8% CREC
and 22.9% CRKP strains had a MIC of 4 μg/mL for imipenem,
respectively. About 97% of XDRAB and 84% of XDRPA isolates
had MICs of 16 μg/mL for imipenem, while 65.6% XDRAB
strains had a MIC of 1 μg/mL for tigecycline. Detailed infor-
mation on MIC distributions is shown in Figs. 4 to 7.DiscussionSigniﬁcant rates of CR and XDR phenotypes were detected
among bloodstream Gram-negative samples isolated in China in
2013. As expected, regional and clinical differences were noted
in the distribution of the different bacteria strains.
The prevalence of CRKP has gradually increased from 3.2%
in 2009 to 6.0% in 2012 [12] and stands at 5.5% for blood-origin
isolates in 2013 in China. Interestingly, the geographic distri-
bution of CRKP in 2013 paralleled the national data in 2009,
which revealed high incidence of CRKP around the Yangtze
River, covering East and Central regions of China [1,13]. A
series of molecular epidemiology studies on CRE in China has
shown that the occurrence of outbreaks caused by KPC-2
producing K. pneumoniae in these regions was due to spread
of the predominant clone ST11, which is a variant of interna-
tional clone ST258 [14,15]. ST258 is strongly associated with
KPC production and with isolates exhibiting multidrug resis-
tance, but it may have inherent traits responsible for its high
rate of transmissibility due to two distinct genetic clades with a
hot spot for DNA recombination [16]. Further studies to un-
ravel possible reasons for ST11’s long-term spread in the East
region, by analysing the genomic difference between ST11 and
ST258, are warranted. More than 70% of CRKP isolates had a
MIC of 8 μg/mL for imipenem or meropenem, suggesting a
high possibility of treatment failure if using carbapenems as
monotherapy or in combination therapy [7]. All CRKP isolates
were susceptible to tigecycline with a MIC90 of 1 μg/mL, and
55.3% CRKP strains were also susceptible to amikacin, sug-
gesting that CRKP infections could be managed by combining
tigecycline with an aminoglycoside, which has frequently served
as a last-resort drug and is prescribed as a part of combination
schemes against CRE with aminoglycoside in China [8].European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S1–S8
nses/by-nc-nd/4.0/)
FIG. 4. Minimum inhibitory concentration (MIC) distributions of antimicrobials against 138 carbapenem-resistant Escherichia coli isolates in 2103 in
China.
CMI Xu et al. Epidemiology of resistant bacteria in China S5However, it is important to note that the US Food and Drug
Administration has issued a warning on higher mortality with
tigecycline compared to other antibiotics, and thus it is a drug
of last resort.
Previous studies show that elderly patients, severe under-
lying illness and ICU admission are the likely major risk factorsFIG. 5.Minimum inhibitory concentration (MIC) distributions of antimicrobial
in China.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on beh
This is an open access artiassociated with CRE bacteremia [17]. The present ﬁndings are
in agreement with these previous studies but differ in the
higher prevalence of CRKP in the pediatric and newborn
groups compared to the elderly group, especially in regions
other than the East, the epidemic area of CRKP in China [3]. A
similar situation was observed for XDRAB. This could be dues against 333 carbapenem-resistant Klebsiella pneumoniae isolates in 2013
alf of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S1–S8
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FIG. 6. Minimum inhibitory concentration (MIC) distributions of antimicrobials against 256 multidrug-resistant Acinetobacter baumannii isolates in 2013
in China.
S6 Clinical Microbiology and Infection, Volume 22 Number S1, March 2016 CMIto antibiotic abuse in the pediatric/neonate population [18] or
an outbreak of CRKP or XDRAB in local wards or hospitals
that would have been easily identiﬁed by molecular assays if
the isolates were still available for such testing. Indeed, there
are limited reports on outbreaks of CRE in pediatric and
newborn ICU, and even CRE intestinal colonization in one
region of China, due to inadequate infection control practices
[19,20].
The high prevalence of CRAB in China presents challenges
to physicians in the management of infections caused by such
strains. Speciﬁcally, the high rates of CRAB from blood pre-
sents a huge dilemma to clinicians regarding the choice of
empirical antibiotic treatment, as inappropriate empirical
treatment can lead to high mortality rates. In this study,
A. baumannii was the fourth most prevalent pathogen (5.6%)
among all Gram-negative bacteria isolated from blood and had
the highest CR rate (53.5%) and the highest XDR rate (13.7%)FIG. 7. Minimum inhibitory concentration (MIC) distributions of antimicrobia
isolates in 2013 in China.
Clinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceamong all the tested isolates in 2013. All XDRAB isolates in the
present study had a MIC of 6 μg/mL for carbapenems, which,
if considered in light of a previous report in China, in which
84.7% of CRAB isolates of ST22 had imipenem MICs from 32
to 128 mg/L [4], suggests that it is not appropriate to treat
patients with a carbapenem alone or in combination with other
antibiotics for infections caused by such strains. Multiple
studies suggest that a sulbactam-based combination therapy is a
more appropriate treatment option for XDRAB, including
tigecycline and sulbactam combinations [21]. At the same time,
studies reveal that clinical outcomes for tigecycline and
XDRAB infections therapy are also closely related to the
in vitro MIC [22]. Speciﬁcally, if the MIC is >1 μg/mL, a higher
dosage schedule (75 or 100 mg every 12 hours after a loading
dose of 150 or 200 mg, respectively) is required. Our study
showed that 65.6% of XDRAB had a MIC of 1 μg/mL for
tigecycline and that about 15.6% of the strains had MICs ofls against 82 extensively drug-resistant strains of Pseudomonas aeruginosa
European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, S1–S8
nses/by-nc-nd/4.0/)
CMI Xu et al. Epidemiology of resistant bacteria in China S72 μg/mL, implying that about half of the infections caused by
XDRAB in the present study could use conventional tigecycline
standard-dosage regimen.
The epidemiologic characteristic of XDRPA is still insufﬁ-
cient in China. CHINET data demonstrate that resistance levels
have stably decreased for all of the antimicrobial agents,
including imipenem and meropenem, among P. aeruginosa over
a decade [23], and our data also reveal a lower prevalence of
XDRPA in blood culture compared to XDR K. pneumoniae and
XDRAB. However, XDRPA infection may pose a more difﬁcult
challenge for the treatment as a result of fewer selective drugs
in China, as colistin is not marketed in China.
Predictably, ICU admission was the most important risk
factor for acquiring CRAB (prevalence rate of 71.6%) and
XDRAB (prevalence rate of 18.8%). The high prevalence of
CRAB in China is most likely due to the emergence of the
dominant clone CC92, which was ﬁrst reported in 16 cities in
China and is the most prevalent in nine Asian countries
monitored by the Asian Network for Surveillance of Resistant
Pathogens (83/103 isolates, 76.9%) [4,24,25]. Unfortunately,
unlike CRE, which has a low prevalence in most regions, minor
differences existed in the geographic distribution of CRAB, with
very high prevalence in all regions, ranging from 48.1 to 72.5%.
This might be due to greater difﬁculties in controlling the
spread of CRAB in ICUs and elsewhere. Studies have shown
that A. baumannii can be isolated from anywhere in the ICU and
is easily transmitted between patients and health staff [26].
Some new infection control technologies, including using
genome sequencing to reconstruct chains of transmission or
establishing data-driven mathematical models to evaluate the
nurse–patient ratio, may possibly assist in the development of
more effective infection control strategies to control or end
outbreaks of CRAB in the future [27,28].
The overall prevalence rate of CREC from blood was 1.0%,
with a fairly uniform distribution in all seven geographic regions,
which is consistent with the national data from 2009 to 2012
[23]. All CREC isolates were susceptible to polymyxin B and
tigecycline, and 83.3 and 44.4% were also susceptible to ami-
kacin and gentamicin, respectively. Furthermore, 55.8% of the
CREC strains had a MIC of 4 μg/mL (to imipenem), which
suggests that carbapenems could provide some therapeutic
beneﬁt in infections caused by CREC with high-dose/prolonged
infusion of carbapenems. Carbapenems in combination with
aminoglycoside seem to be a preferred treatment option in
resource-constrained settings [8].
Our study has some limitations. Firstly, this study does not
reﬂect the overall situation of the epidemiology of CRE,
XDRAB and XDRPA in China as isolates from other sources
(urine, respiratory tract and other samples) were not included
as a result of insufﬁcient data. However, according to availableClinical Microbiology and Infection © 2015 The Authors. Published by Elsevier Ltd on beh
This is an open access artidata in the CHINET program, the prevalence of these organ-
isms from other samples is actually as high as that from blood,
and the geographic and clinical distributions are also similar
[23]. However, we think that the epidemiology of CRE, XDRAB
and XDRPA strains from bloodstream infection has a more
signiﬁcant clinical guidance value. Secondly, because of the small
number of CRKP isolates in the pediatric and newborn groups,
it was not possible to draw ﬁrm conclusions regarding whether
an outbreak had occurred. Thirdly, compared to standard
microbroth diffusion assay, there are few major errors and
some minimal errors in detecting MICs by automation. For
example, the imipenem minimal errors had a Vitek 2 MIC that
was 1 log2 dilution above the broth microdilution (BMD) MIC
and occurred for four Enterobacter, four Providencia stuartii,
three Morganella morganii, two Proteus vulgaris, one Serratia
marcescens and one Citrobacter species isolate [29]. Further-
more, it may erroneously report some susceptible isolates as
intermediate if determined MIC for tigecycline against
A. baumannii [30]. Finally, in this surveillance study, 208 hospi-
tals, including 193 tertiary-care hospitals, were enrolled on the
basis of their high quality of laboratory testing and available
surveillance information. This might not be a representative
sample of all hospitals and might be biased towards hospitals
with higher rates of resistance, being tertiary care, probably
larger and with advanced microbiology laboratories.
In conclusion, this study indicates a high prevalence of CRKP
and XDRAB, which is increasing in China, with large differences
in distribution by region and population groups. Infection
control strategies should be strengthened in high CR-
prevalence areas. Carbapenems, tigecycline and aminoglyco-
sides can still be used as alternative treatment options for in-
fections caused by CR or XDR strains based on the lower MIC
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